Here is your latest research news for August, 2022. Stay up to date on monthly research updates with us! Sanguine is currently recruiting for 51 research studies. Check out the latest Sanguine studies here.
Monkeypox: The U.S. is planning to stretch its monkeypox vaccine supply by utilizing an injection method that uses one fifth of a regular dose. This could help alleviate supply shortages.
Long-COVID: New research focuses on Long-COVID or Long-Haul COVID describes post-viral symptoms that are ongoing after infection. Long-COVID involves neuroinflammation and presents similar symptoms as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Researchers believe the conditions may be related.
Brain and Gut: New research suggests that neurodegenerative diseases like Parkinson’s may be associated with issues in the microbiome and the gut rather than exclusively with the nervous system. Researchers believe this may be through the gut-brain axis.
Sickle Cell Disease Research News Updates
Corticosteroids and VOEs: Recent research has found that there is a correlation between systemic corticosteroid exposure in sickle cell patients and vaso-occlusive episodes (VOE). Corticosteroid exposure is associated with an increased risk of VOE related hospitalizations.
Pfizer Buys GBT: In a recent deal, Pfizer has acquired Global Blood Therapeutics- a leader in sickle cell treatment development. GBT has many potential sickle cell treatments in the pipeline including inclacumab and GBT601.
Lupus Research News Updates
Litifilimab: In a phase 2 clinical trial, litifilimab was an effective treatment for reducing skin disease activity in patients with cutaneous lupus erythematosus (CLE).
NPSLE: In a research study conducted at Hokkaido University, researchers focused on neuropsychiatric systemic lupus erythromatosus (NPSLE) and have identified a stress-induced molecular pathway that affects NPSLE.
Autoimmune Disease Research News Updates
Leaky Gut: According to autoimmune research, bacteria toxins can leak into the “intestines” in a process called Increased Permeability (IP, which can trigger the immune system and increase the risk of developing conditions like Celiac Disease, Crohn’s Disease, IBD, depression, MS, and lupus.
Lyme Disease: Pfizer is starting a phase 3 clinical trial for a vaccine that protects against Lyme Disease. Lyme Disease results from bacteria carried by ticks and infects nearly 500,000 people each year.
By: Neelem Sheikh